{ "company": "Revvity", "ticker": "RVTY", "period": { "from": "2026-03-21", "to": "2026-04-20", "days": 30 }, "sentiment_breakdown": { "positive": 21, "negative": 18, "neutral": 36 }, "synthesis": { "executive_summary": "Sentiment analysis for Revvity (RVTY) from 2026-03-21 to 2026-04-20. Analyzed 75 items across FDA and news sources.", "key_findings": [], "overall_sentiment": "neutral" }, "top_positive": [ { "title": "Nephron Research gets more bullish on Revvity, upgrades shares", "date": "2026-03-26", "source": "news", "score": 0.991 }, { "title": "[Latest] Global Environmental Mass Spectrometry Market Size/Share Worth USD 6.47 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)", "date": "2026-04-02", "source": "news", "score": 0.859 }, { "title": "Revvity Inc. stock outperforms competitors on strong trading day", "date": "2026-04-17", "source": "alpha_vantage", "score": 0.711 }, { "title": "Revvity Inc. stock outperforms competitors on strong trading day", "date": "2026-04-08", "source": "alpha_vantage", "score": 0.711 }, { "title": "Allergy Diagnostic Market by Product & Service, Test Type, Allergen, End User - Global Forecast to 2031", "date": "2026-04-13", "source": "news", "score": 0.602 }, { "title": "Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - Asia-Pacific NGS Market Poised for Fastest Growth, Driven by Large-Scale Genomic Projects and the Rising Need for Precision Medicine", "date": "2026-04-10", "source": "news", "score": 0.557 }, { "title": "Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know", "date": "2026-04-18", "source": "news", "score": 0.527 }, { "title": "Keys to Succeed in the Booming $300 Million Optical Genome Mapping Market 2026-2030: Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies Lead", "date": "2026-04-13", "source": "alpha_vantage", "score": 0.494 }, { "title": "Keys to Succeed in the Booming $300 Million Optical Genome Mapping Market 2026-2030: Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies Lead", "date": "2026-04-13", "source": "alpha_vantage", "score": 0.494 }, { "title": "Machine says go, doctor says no: an ecological momentary assessment analysis examining clinicians' perceptions of, and their antibiotic prescribing behaviour when using rapid molecular diagnostic tests in intensive care.", "date": "2026 Mar 2", "source": "pubmed", "score": 0.494 } ], "top_negative": [ { "title": "Template-driven scaffolding of SCFFBXO42 regulates PP2A degradation", "date": "2026-04-15", "source": "news", "score": -0.869 }, { "title": "Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity", "date": "2026-03-25", "source": "news", "score": -0.66 }, { "title": "Feasibility of deep learning-based cancer detection in ultrasound microvascular images.", "date": "2026-04-20", "source": "pubmed", "score": -0.66 }, { "title": "Exe file from discord putting malware on device", "date": "2026-04-17", "source": "news", "score": -0.612 }, { "title": "A µ-opioid receptor superagonist analgesic with minimal adverse effects", "date": "2026-04-01", "source": "news", "score": -0.612 }, { "title": "Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026", "date": "2026-04-16", "source": "alpha_vantage", "score": -0.572 }, { "title": "Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026", "date": "2026-04-16", "source": "alpha_vantage", "score": -0.572 }, { "title": "Revvity downgraded to Equal Weight from Overweight at Barclays", "date": "2026-04-14", "source": "alpha_vantage", "score": -0.561 }, { "title": "Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118", "date": "2026-04-14", "source": "alpha_vantage", "score": -0.561 }, { "title": "Barclays Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $95", "date": "2026-04-14", "source": "alpha_vantage", "score": -0.496 } ], "raw_data": { "total_items": 75, "items": [ { "source": "news", "source_name": "MyMotherLode.com", "title": "Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know", "description": "Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Knowmymotherlode.com", "url": "http://money.mymotherlode.com/clarkebroadcasting.mymotherlode/article/stockstory-2026-4-17-revvity-bio-techne-corcept-supernus-pharmaceuticals-and-phibro-animal-health-shares-skyrocket-what-you-need-to-know", "date": "2026-04-18", "published_at": "2026-04-18T00:42:25Z", "sentiment": { "label": "positive", "score": 0.527, "confidence": 0.53 } }, { "source": "news", "source_name": "BleepingComputer", "title": "Exe file from discord putting malware on device", "description": "Exe file from discord putting malware on device - posted in Virus, Trojan, Spyware, and Malware Removal Help: \nI clicked on a file from a friends hacked account that installed malware on my device. It stole my cookies, discord token and email password. I have…", "url": "https://www.bleepingcomputer.com/forums/t/815521/exe-file-from-discord-putting-malware-on-device/", "date": "2026-04-17", "published_at": "2026-04-17T02:54:19Z", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "news", "source_name": "Nature.com", "title": "Template-driven scaffolding of SCFFBXO42 regulates PP2A degradation", "description": "The E3 ligase SCFFBXO42 degrades holoenzyme-free PP2Ac in complex with the coiled-coil protein CCDC6 to maintain cancer cell fitness", "url": "https://www.nature.com/articles/s41586-026-10368-z", "date": "2026-04-15", "published_at": "2026-04-15T00:00:00Z", "sentiment": { "label": "negative", "score": -0.869, "confidence": 0.87 } }, { "source": "news", "source_name": "24/7 Wall St.", "title": "Here Are Tuesday’s Top Wall Street Analyst Research Calls: Biogen, Birkenstock, Fastly, Ford, Lennox International, Netskope, SanDisk, Tesla, and More", "description": "Pre-Market Stock Futures: The futures are trading mixed this morning, after what started as another week of the same old song and dance yesterday, before...", "url": "https://247wallst.com/investing/2026/04/14/here-are-tuesdays-top-wall-street-analyst-research-calls-biogen-birkenstock-fastly-ford-lennox-international-netskope-sandisk-tesla-and-more/", "date": "2026-04-14", "published_at": "2026-04-14T11:58:19Z", "sentiment": { "label": "positive", "score": 0.202, "confidence": 0.2 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Allergy Diagnostic Market by Product & Service, Test Type, Allergen, End User - Global Forecast to 2031", "description": "The allergy diagnostic market is set to surge, projected to reach USD 10.77 billion by 2030 from USD 6.80 billion in 2025, at a CAGR of 9.6%. Technological innovation in diagnostics, such as multiplex immunoassays and molecular allergology, drives this growth…", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272461/28124/en/Allergy-Diagnostic-Market-by-Product-Service-Test-Type-Allergen-End-User-Global-Forecast-to-2031.html", "date": "2026-04-13", "published_at": "2026-04-13T12:00:00Z", "sentiment": { "label": "positive", "score": 0.602, "confidence": 0.6 } }, { "source": "news", "source_name": "Barchart.com", "title": "What to Expect From Revvity's Next Quarterly Earnings Report", "description": "Revvity will release its first-quarter earnings soon, and analysts anticipate a low single-digit bottom-line growth.", "url": "https://www.barchart.com/story/news/1264071/what-to-expect-from-revvity-s-next-quarterly-earnings-report", "date": "2026-04-12", "published_at": "2026-04-12T15:49:34Z", "sentiment": { "label": "positive", "score": 0.128, "confidence": 0.13 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global Next-Generation Sequencing (NGS) Market to Double in Size by 2030 - Asia-Pacific NGS Market Poised for Fastest Growth, Driven by Large-Scale Genomic Projects and the Rising Need for Precision Medicine", "description": "Dublin, April 10, 2026 (GLOBE NEWSWIRE) -- The \"Next-Generation Sequencing Market by Product Type, Technology, Workflow, Services, Application - Global Forecast to 2030\" has been added to ResearchAndMarkets.com's offering.The next-generation sequencing (NGS) …", "url": "https://www.globenewswire.com/news-release/2026/04/10/3271604/28124/en/Global-Next-Generation-Sequencing-NGS-Market-to-Double-in-Size-by-2030-Asia-Pacific-NGS-Market-Poised-for-Fastest-Growth-Driven-by-Large-Scale-Genomic-Projects-and-the-Rising-Need-.html", "date": "2026-04-10", "published_at": "2026-04-10T09:45:00Z", "sentiment": { "label": "positive", "score": 0.557, "confidence": 0.56 } }, { "source": "news", "source_name": "Nature.com", "title": "Synthetic super-enhancers enable precision viral immunotherapy", "description": "Synthetic super-enhancers enable specific delivery of anticancer payloads, achieving tumour elimination after a single dose in a mouse model of aggressive glioblastoma.", "url": "https://www.nature.com/articles/s41586-026-10329-6", "date": "2026-04-08", "published_at": "2026-04-08T00:00:00Z", "sentiment": { "label": "negative", "score": -0.153, "confidence": 0.15 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Global DNA Read, Write and Edit Market to Surge to $67.7 Billion by 2030, Driven by CRISPR Advances, Genomic Diagnostics and Expanding Clinical Applications", "description": "Rapid expansion in clinical applications, rising demand for genomic diagnostics, and increased investment in CRISPR-based therapeutics are fueling demand....", "url": "https://www.globenewswire.com/news-release/2026/04/07/3269543/0/en/Global-DNA-Read-Write-and-Edit-Market-to-Surge-to-67-7-Billion-by-2030-Driven-by-CRISPR-Advances-Genomic-Diagnostics-and-Expanding-Clinical-Applications.html", "date": "2026-04-07", "published_at": "2026-04-07T17:44:00Z", "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "[Latest] Global Environmental Mass Spectrometry Market Size/Share Worth USD 6.47 Billion by 2035 at a 7.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)", "description": "[220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global Environmental Mass Spectrometry Market size & share revenue was valued at approximately USD 2.84 Billion in 2025 and is expected…", "url": "https://www.globenewswire.com/news-release/2026/04/02/3267246/0/en/Latest-Global-Environmental-Mass-Spectrometry-Market-Size-Share-Worth-USD-6-47-Billion-by-2035-at-a-7-6-CAGR-Custom-Market-Insights-Analysis-Outlook-Leaders-Report-Trends-Forecast-.html", "date": "2026-04-02", "published_at": "2026-04-02T11:30:00Z", "sentiment": { "label": "positive", "score": 0.859, "confidence": 0.86 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Here’s Artisan Mid Cap Value Fund’s Investment Thesis for Revvity (RVTY)", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_c5216dc8-8c36-4957-a877-72cca4ac0804", "date": "2026-04-01", "published_at": "2026-04-01T15:04:29Z", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "news", "source_name": "GlobeNewswire", "title": "Protein Chip Market Size is Expected to Reach USD 4.79 Billion by 2035 Owing to the Rapid Adoption of Mass-screening Proteomics Technologies Globally | SNS Insider", "description": "Protein chip market grows to USD 4.79 Billion by 2035 at 6.89% CAGR, driven by proteomics research, and rising clinical diagnostics adoption....", "url": "https://www.globenewswire.com/news-release/2026/04/01/3266380/0/en/Protein-Chip-Market-Size-is-Expected-to-Reach-USD-4-79-Billion-by-2035-Owing-to-the-Rapid-Adoption-of-Mass-screening-Proteomics-Technologies-Globally-SNS-Insider.html", "date": "2026-04-01", "published_at": "2026-04-01T09:30:00Z", "sentiment": { "label": "neutral", "score": 0.026, "confidence": 0.03 } }, { "source": "news", "source_name": "Nature.com", "title": "A µ-opioid receptor superagonist analgesic with minimal adverse effects", "description": "N-desethyl-fluornitrazene is a µ-opioid receptor agonist derived from nitazenes that has supramaximal intrinsic efficacy that produces analgesia with minimal adverse effects in rodent models.", "url": "https://www.nature.com/articles/s41586-026-10299-9", "date": "2026-04-01", "published_at": "2026-04-01T00:00:00Z", "sentiment": { "label": "negative", "score": -0.612, "confidence": 0.61 } }, { "source": "news", "source_name": "Nature.com", "title": "Mosaic gastruloids reveal a temporal restriction for developmental cell competition", "description": "Frenster et al. utilize mosaic mouse gastruloids as a model of cell fitness and competition, identifying a temporal window between primed pluripotency and early gastrulation during which cell competition occurs in mammalian embryogenesis.", "url": "https://www.nature.com/articles/s41556-026-01923-x", "date": "2026-04-01", "published_at": "2026-04-01T00:00:00Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Yahoo Entertainment", "title": "Stifel Maintains a Hold Rating on Revvity (RVTY)", "description": "", "url": "https://consent.yahoo.com/v2/collectConsent?sessionId=1_cc-session_5264e652-64a8-4995-bdc5-fa1ad7e19dbd", "date": "2026-03-27", "published_at": "2026-03-27T07:29:27Z", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "news", "source_name": "Thefly.com", "title": "Nephron Research gets more bullish on Revvity, upgrades shares", "description": "See the rest of the story here.\n\nthefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…", "url": "https://www.thefly.com/RVTY", "date": "2026-03-26", "published_at": "2026-03-26T11:13:51Z", "sentiment": { "label": "positive", "score": 0.991, "confidence": 0.99 } }, { "source": "news", "source_name": "Nature.com", "title": "Ectopic NMDAR expression in cancer unmasks germline-encoded autoimmunity", "description": "NMDAR expression is sufficient to induce B cell recruitment and affinity maturation, resulting in receptor-modulating antibodies that connect anti-cancer immunity and autoimmunity.", "url": "https://www.nature.com/articles/s41586-026-10278-0", "date": "2026-03-25", "published_at": "2026-03-25T00:00:00Z", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "alpha_vantage", "title": "The Bull Case For Revvity (RVTY) Could Change Following Its New AI-Enabled Oncology Platform Push", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/the-bull-case-for-revvity-rvty-could-change-following-its-ne", "date": "2026-04-19", "summary": "Revvity recently launched new AI-enabled oncology platform tools and molecular cloning software, Signals BioDesign, aimed at streamlining cancer and biologics research. This strategic pivot towards higher-margin software and integrated life-science tools could significantly impact its investment narrative by offsetting pressures in diagnostics and funding-sensitive research markets. While these advancements are promising, investors should also consider risks like regulatory changes in China affe", "sentiment_score": 0.402547, "sentiment_label": "Bullish", "relevance_score": 0.973026, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity (NYSE:RVTY) Downgraded by Wall Street Zen to \"Hold\"", "url": "https://www.marketbeat.com/instant-alerts/revvity-nyservty-downgraded-by-wall-street-zen-to-hold-2026-04-18/", "date": "2026-04-18", "summary": "Wall Street Zen has downgraded Revvity (NYSE:RVTY) from a \"Buy\" to a \"Hold\" rating, aligning with the broader analyst consensus. The company, which recently reported stronger-than-expected earnings and set a positive FY2026 guidance, nevertheless faces a \"relatively rich valuation\" with a P/E of 45.19. The average analyst rating is now \"Hold\" with an average price target of $110.17, despite various recent adjustments from other firms.", "sentiment_score": -0.243907, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health Shares Skyrocket, What You Need To Know", "url": "https://www.theglobeandmail.com/investing/markets/stocks/CORT/pressreleases/1375699/revvity-bio-techne-corcept-supernus-pharmaceuticals-and-phibro-animal-health-shares-skyrocket-what-you-need-to-know/", "date": "2026-04-17", "summary": "Shares of Revvity, Bio-Techne, Corcept, Supernus Pharmaceuticals, and Phibro Animal Health experienced significant gains following the reopening of the Strait of Hormuz. This event signals reduced global logistics and energy costs, particularly benefiting healthcare providers and medical device manufacturers due to lower operational and shipping expenses. The \"risk-on\" sentiment driven by a ceasefire has also spurred investment in high-growth biotech and pharmaceutical companies, as macroeconomi", "sentiment_score": 0.531174, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.296, "confidence": 0.3 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-e9002bdf-edd57f1a36fd", "date": "2026-04-17", "summary": "Shares of Revvity Inc. (RVTY) rose 5.03% to $93.96 on Friday, outperforming the broader stock market. This rise snapped a two-day losing streak for the company's stock. The S&P 500 Index and Dow Jones Industrial Average also saw gains during the favorable trading session.", "sentiment_score": 0.47445, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "Revvity CEO joins June 9 Goldman healthcare conference fireside chat", "url": "https://www.stocktitan.net/news/RVTY/revvity-to-present-at-upcoming-investor-zfxb9qhuwupp.html", "date": "2026-04-17", "summary": "Revvity, Inc. (NYSE: RVTY) announced it will present at two upcoming investor conferences: the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Revvity’s CEO, Prahlad Singh, will participate in a fireside chat at the Goldman Sachs event. The presentations will provide updates on the company's strategic priorities, with live audio webcasts and replays available on Revvity's investor relations website.", "sentiment_score": 0.130779, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Assessing Revvity (RVTY) Valuation After Signals BioDesign Launch And Earnings Anticipation", "url": "https://www.sahmcapital.com/news/content/assessing-revvity-rvty-valuation-after-signals-biodesign-launch-and-earnings-anticipation-2026-04-16", "date": "2026-04-17", "summary": "Revvity (RVTY) recently launched Signals BioDesign, a cloud-native molecular cloning platform, which is drawing investor attention ahead of upcoming earnings. Despite short-term gains, the stock has shown longer-term declines. While a popular narrative suggests RVTY is 22.3% undervalued with a fair value of $119.56 due to expected margin expansion and a product mix shift, its current P/E ratio is significantly higher than its fair value and industry averages, indicating mixed signals on its valu", "sentiment_score": 0.303348, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock underperforms Thursday when compared to competitors", "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-underperforms-thursday-when-compared-to-competitors-983d64ce-b1d18f741fee?mod=mw_quote_news", "date": "2026-04-16", "summary": "Revvity Inc. (RVTY) stock fell 3.63% to $89.53 on Thursday, experiencing its second consecutive day of losses despite a generally favorable trading session for the broader market. The S&P 500 Index and the Dow Jones Industrial Average both saw gains, rising 0.26% and 0.24% respectively. This indicates Revvity's underperformance relative to its competitors and the overall market.", "sentiment_score": -0.634615, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026", "url": "https://www.pharmiweb.com/press-release/2026-04-16/revvity-showcases-integrated-cancer-research-solutions-at-aacr-annual-meeting-2026", "date": "2026-04-16", "summary": "Revvity is showcasing its latest integrated cancer research solutions at the AACR Annual Meeting 2026, held in San Diego from April 17-22. The company's comprehensive suite of research-use-only oncology solutions, including advanced imaging systems, AI software, and reagents, aims to accelerate discoveries from preclinical to translational research. These innovations are designed to streamline workflows, reduce variability, and empower scientists with AI-driven insights to achieve better patient", "sentiment_score": 0.454829, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Revvity Showcases Integrated Cancer Research Solutions at AACR Annual Meeting 2026", "url": "https://www.businesswire.com/news/home/20260416903856/en/Revvity-Showcases-Integrated-Cancer-Research-Solutions-at-AACR-Annual-Meeting-2026", "date": "2026-04-16", "summary": "Revvity, Inc. is showcasing its latest integrated cancer research solutions at the AACR Annual Meeting 2026, offering a comprehensive suite of tools from sample preparation to data analysis. These solutions leverage AI-driven insights and advanced technologies to accelerate discoveries and improve patient outcomes. The company highlights products like the Opera Phenix™ OptIQ system and Living Image™ Synergy AI software, aiming to empower researchers with end-to-end workflows.", "sentiment_score": 0.52391, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.572, "confidence": 0.57 } }, { "source": "alpha_vantage", "title": "Revvity to Present at Upcoming Investor Conferences", "url": "https://www.businesswire.com/news/home/20260416523258/en/Revvity-to-Present-at-Upcoming-Investor-Conferences", "date": "2026-04-16", "summary": "Revvity, Inc. (NYSE: RVTY) announced it will present at the BofA Securities 2026 Health Care Conference on May 13, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, 2026. Company representatives, including senior vice president Steve Willoughby and CEO Prahlad Singh, will provide updates on the company and its strategic priorities. Live webcasts and replays of the presentations will be available on Revvity's Investor Relations website.", "sentiment_score": 0.12295, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Assessing Revvity (RVTY) Valuation After Signals BioDesign Launch And Earnings Anticipation", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/assessing-revvity-rvty-valuation-after-signals-biodesign-lau", "date": "2026-04-16", "summary": "Revvity (RVTY) recently launched Signals BioDesign, a cloud-native molecular cloning platform, drawing investor attention ahead of its upcoming earnings report. Despite short-term gains, the stock has seen longer-term declines in total shareholder returns over one and three years. Analysts currently deem Revvity undervalued, with a fair value of $119.56, suggesting potential for margin expansion, though its high P/E ratio raises questions about market overpayment for recovery.", "sentiment_score": 0.463718, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.103, "confidence": 0.1 } }, { "source": "alpha_vantage", "title": "Revvity (NYSE:RVTY) Lowered to Equal Weight Rating by Barclays", "url": "https://www.marketbeat.com/instant-alerts/revvity-nyservty-lowered-to-equal-weight-rating-by-barclays-2026-04-15/", "date": "2026-04-15", "summary": "Barclays downgraded Revvity (NYSE:RVTY) from \"overweight\" to \"equal weight\" and set a $95 price target, indicating a modest potential upside. Despite the downgrade, Revvity recently exceeded Q4 earnings expectations with $1.70 EPS and $772.1M revenue, also providing strong FY2026 guidance. Analyst sentiment is mixed, with the stock currently holding an average rating of \"Hold\" and a consensus price target of $110.17.", "sentiment_score": 0.031504, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "The Goldman Sachs Group Lowers Revvity (NYSE:RVTY) Price Target to $95.00", "url": "https://www.marketbeat.com/instant-alerts/the-goldman-sachs-group-lowers-revvity-nyservty-price-target-to-9500-2026-04-14/", "date": "2026-04-15", "summary": "The Goldman Sachs Group has reduced its price target for Revvity (NYSE:RVTY) from $110.00 to $95.00, while maintaining a \"neutral\" rating on the stock. This new target suggests a potential upside of only 0.92% from the previous closing price. Despite the lowered target from Goldman Sachs, Revvity recently exceeded quarterly earnings expectations with $1.70 EPS on $772.1M revenue, and provided FY2026 guidance above analyst estimates.", "sentiment_score": -0.229114, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.128, "confidence": 0.13 } }, { "source": "alpha_vantage", "title": "Barclays downgrades Revvity (RVTY)", "url": "http://www.msn.com/en-us/money/savingandinvesting/barclays-downgrades-revvity-rvty/ar-AA20VKVU?apiversion=v2&domshim=1&noservercache=1&noservertelemetry=1&batchservertelemetry=1&renderwebcomponents=1&wcseo=1", "date": "2026-04-15", "summary": "Barclays has changed its rating for Revvity (RVTY) stock. The firm lowered its rating on Revvity shares. This action indicates a revised outlook on the company's financial prospects or valuation by the analyst.", "sentiment_score": -0.411589, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.2, "confidence": 0.2 } }, { "source": "alpha_vantage", "title": "Barclays Downgrades Revvity(RVTY.US) to Hold Rating, Cuts Target Price to $95", "url": "https://www.moomoo.com/news/post/68285960/barclays-downgrades-revvity-rvtyus-to-hold-rating-cuts-target-price", "date": "2026-04-14", "summary": "Barclays has downgraded Revvity (RVTY.US) from an Overweight to a Hold rating. The investment bank also lowered its target price for Revvity shares to $95. This revised outlook suggests a more cautious stance on the company's stock by Barclays analysts.", "sentiment_score": -0.613081, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.496, "confidence": 0.5 } }, { "source": "alpha_vantage", "title": "Is Revvity (RVTY) Starting To Look Attractive After Recent Share Price Weakness", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-rvty/revvity/news/is-revvity-rvty-starting-to-look-attractive-after-recent-sha", "date": "2026-04-14", "summary": "Revvity (RVTY) has seen recent share price weakness, with a 5.6% decline year-to-date and a 4.8% decline over the past year. A Discounted Cash Flow (DCF) analysis suggests the stock is undervalued by 31.1% at its current price of US$92.64, indicating a fair value of around $134.50 per share. However, its Price/Earnings ratio of 43.18x is above the industry average and its estimated \"Fair Ratio\" of 22.44x, suggesting it is overvalued from an earnings perspective.", "sentiment_score": 0.261016, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.318, "confidence": 0.32 } }, { "source": "alpha_vantage", "title": "Massachusetts Financial Services Co. MA Has $106.19 Million Stake in Revvity Inc. $RVTY", "url": "https://www.marketbeat.com/instant-alerts/filing-massachusetts-financial-services-co-ma-has-10619-million-stake-in-revvity-inc-rvty-2026-04-14/", "date": "2026-04-14", "summary": "Massachusetts Financial Services Co. trimmed its stake in Revvity Inc. by 4.2%, now holding 1,097,539 shares valued at $106.19 million, though other institutional investors like Goldman Sachs and Millennium Management increased their positions. Revvity reported strong quarterly earnings, beating analyst estimates and providing positive FY2026 guidance, while analysts currently rate the stock as a \"Hold\" with a target price of $112.92. The company also announced a quarterly dividend and its share", "sentiment_score": 0.259695, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.982228, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity downgraded to Equal Weight from Overweight at Barclays", "url": "https://www.tipranks.com/news/the-fly/revvity-downgraded-to-equal-weight-from-overweight-at-barclays-thefly-news", "date": "2026-04-14", "summary": "Barclays analyst Luke Sergott downgraded Revvity (RVTY) to Equal Weight from Overweight, lowering the price target to $95 from $118. The downgrade is attributed to potential margin risk ahead of the company's Q1 report and competitive threats in flow cytometry reagents from Waters. Although flow reagents represent a small portion of Revvity's overall revenue, they are crucial for the company to achieve its growth targets.", "sentiment_score": -0.447286, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.561, "confidence": 0.56 } }, { "source": "alpha_vantage", "title": "Barclays Downgrades Revvity to Equalweight From Overweight, Adjusts Price Target to $95 From $118", "url": "https://www.marketscreener.com/news/barclays-downgrades-revvity-to-equalweight-from-overweight-adjusts-price-target-to-95-from-118-ce7e50dfdb8bf126", "date": "2026-04-14", "summary": "Barclays has downgraded Revvity (RVTY) from Overweight to Equalweight, simultaneously lowering its price target from $118 to $95. This adjustment reflects a more cautious outlook on the company's stock performance. The article also mentions recent price target adjustments from other financial institutions like Goldman Sachs and TD Cowen.", "sentiment_score": -0.403827, "sentiment_label": "Bearish", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.561, "confidence": 0.56 } }, { "source": "alpha_vantage", "title": "RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data", "url": "https://uk.finance.yahoo.com/news/rvty-unveils-signals-biodesign-faster-145800155.html", "date": "2026-04-14", "summary": "Revvity, Inc. (RVTY) has launched Signals BioDesign, a new cloud-based molecular cloning platform aimed at accelerating R&D for biotech and pharmaceutical companies. This platform simplifies complex cloning workflows, offers scalable collaboration, and integrates with the existing Signals One platform to speed up drug development. Despite a recent slight dip in stock, this launch is expected to enhance Revvity's software portfolio, drive recurring revenues, and strengthen its market position in ", "sentiment_score": 0.438967, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity Q1 2026 Earnings Forecast & Stock Analysis | Barchart Report - News and Statistics", "url": "https://www.indexbox.io/blog/revvity-q1-2026-earnings-preview-analysts-project-102-eps/", "date": "2026-04-13", "summary": "Analysts project Revvity will report $1.02 EPS for Q1 2026, marking a slight increase year-over-year, with the company consistently exceeding Wall Street estimates in its recent quarterly reports. Despite this, Revvity's stock has declined over the past year, attributed to concerns over new international trade policies, contrasting with gains in the broader market and healthcare sector. The overall analyst consensus is moderately positive, recommending buying or holding, with an average price ta", "sentiment_score": 0.284703, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock underperforms Monday when compared to competitors despite daily gains", "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-underperforms-monday-when-compared-to-competitors-despite-daily-gains-e8579041-603c3530b2c4?mod=mw_quote_news", "date": "2026-04-13", "summary": "Revvity Inc. (RVTY) stock saw a gain of 3.17% on Monday, closing at $92.64, yet still underperformed against the broader market indices like the S&P 500 Index and the Dow Jones Industrial Average. The company's stock remains significantly below its 52-week high of $118.30.", "sentiment_score": 0.025126, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "negative", "score": -0.458, "confidence": 0.46 } }, { "source": "alpha_vantage", "title": "RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data", "url": "https://finance.yahoo.com/sectors/healthcare/articles/rvty-unveils-signals-biodesign-faster-145800155.html", "date": "2026-04-13", "summary": "Revvity, Inc. (RVTY) has launched Signals BioDesign, a cloud-based molecular cloning platform aimed at speeding up R&D in biotech and pharmaceuticals. This new platform, part of Revvity Signals Software, is designed to simplify complex cloning workflows and enhance collaboration, especially crucial for developing next-generation therapies. Despite a recent slight dip in stock performance, the company anticipates long-term growth by addressing critical needs in biologics research and integrating ", "sentiment_score": 0.471056, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Keys to Succeed in the Booming $300 Million Optical Genome Mapping Market 2026-2030: Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies Lead", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272643/28124/en/Keys-to-Succeed-in-the-Booming-300-Million-Optical-Genome-Mapping-Market-2026-2030-Bionano-Genomics-10x-Genomics-and-Oxford-Nanopore-Technologies-Lead.html", "date": "2026-04-13", "summary": "The optical genome mapping (OGM) market is projected to grow significantly from $0.23 billion in 2025 to $0.74 billion by 2030, driven by the limitations of next-generation sequencing in detecting large structural variants, increased genomic research funding, and rising prevalence of genetic disorders. Key trends include OGM's adoption for structural variant detection in rare diseases and cancer, its use in clinical diagnostics, and the growing demand for precision medicine. Major players like B", "sentiment_score": 0.292799, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.71373, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Goldman Sachs Adjusts Price Target on Revvity to $95 From $110, Maintains Neutral Rating", "url": "https://www.moomoo.com/news/post/68235392/goldman-sachs-adjusts-price-target-on-revvity-to-95-from", "date": "2026-04-13", "summary": "Goldman Sachs has revised its price target for Revvity (NYSE: RVTY) to $95, down from the previous $110. Despite this reduction, the firm has decided to maintain a Neutral rating on the stock. This adjustment reflects a moderated outlook from the investment bank regarding Revvity's stock performance.", "sentiment_score": -0.290416, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "RVTY Unveils Signals BioDesign for Faster Molecular Cloning & R&D Data", "url": "https://www.tradingview.com/news/zacks:f59e954f6094b:0-rvty-unveils-signals-biodesign-for-faster-molecular-cloning-r-d-data/", "date": "2026-04-13", "summary": "Revvity, Inc. (RVTY) has launched Signals BioDesign, a new cloud-based molecular cloning platform through its Revvity Signals Software division. This platform aims to simplify complex cloning workflows for biotech and pharmaceutical R&D teams, enabling faster development of therapies. The move strengthens Revvity's software portfolio and positions it for future growth in predictive biology, especially as the molecular cloning market is projected to reach $6 billion in 2026.", "sentiment_score": 0.318298, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity to Hold Earnings Call on Tuesday, May 5, 2026", "url": "https://www.marketscreener.com/news/revvity-to-hold-earnings-call-on-tuesday-may-5-2026-ce7e50dedb81f020", "date": "2026-04-13", "summary": "Revvity, Inc. (NYSE: RVTY) announced it will release its first quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call on the same day at 7:30 a.m. ET to discuss these results, featuring President and CEO Prahlad Singh and CFO Max Krakowiak. A live audio webcast will be accessible on the Investors section of Revvity's website.", "sentiment_score": 0.106501, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Keys to Succeed in the Booming $300 Million Optical Genome Mapping Market 2026-2030: Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies Lead", "url": "https://www.globenewswire.com/news-release/2026/04/13/3272643/28124/en/keys-to-succeed-in-the-booming-300-million-optical-genome-mapping-market-2026-2030-bionano-genomics-10x-genomics-and-oxford-nanopore-technologies-lead.html", "date": "2026-04-13", "summary": "The optical genome mapping (OGM) market is experiencing rapid growth, projected to expand from $0.23 billion in 2025 to $0.74 billion by 2030, driven by the limitations of next-generation sequencing, increased genomic research funding, and rising demand for advanced cytogenetic techniques. Key players like Bionano Genomics, 10x Genomics, and Oxford Nanopore Technologies are innovating with OGM-based laboratory-developed tests and strategic collaborations to enhance structural variant detection. ", "sentiment_score": 0.259431, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.832475, "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "alpha_vantage", "title": "Revvity launches Signals BioDesign to advance biologic research workflows", "url": "https://www.selectscience.net/article/revvity-launches-signals-biodesign-to-advance-biologic-research-workflows", "date": "2026-04-13", "summary": "Revvity Inc. has launched Signals BioDesign, a cloud-native molecular cloning solution designed to streamline biologics research workflows. This platform enables high-throughput construct design (up to 1,000 constructs) with real-time data sharing and enterprise-grade collaboration for biotech and pharma R&D teams. Signals BioDesign integrates with the Signals One™ platform, positioning research teams for future machine learning applications in sequence optimization and predictive design.", "sentiment_score": 0.472826, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "How Investors Are Reacting To AbCellera Biologics (ABCL) After New Jones Trading Coverage Initiation", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-abcl/abcellera-biologics/news/how-investors-are-reacting-to-abcellera-biologics-abcl-after", "date": "2026-04-13", "summary": "Jones Trading recently initiated coverage on AbCellera Biologics (ABCL), assigning a new rating and highlighting its antibody-medicine pipeline, which has renewed focus on the company's transition to clinical-stage programs. While this attention may boost interest in upcoming clinical data from programs like ABCL635, the core investment narrative remains centered on the company's ability to translate its discovery engine into successful clinical assets, despite ongoing risks such as losses and h", "sentiment_score": 0.196314, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.637085, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity’s IGRA Growth Engine Faces Crucial Test—Can It Offset Eroding China and Immunodiagnostics Headwinds?", "url": "https://www.bitget.com/amp/news/detail/12560605360628", "date": "2026-04-12", "summary": "Revvity (RVTY) faces a critical juncture where its growth in Interferon-Gamma Release Assay (IGRA) testing needs to overcome significant headwinds from declining revenues in China and the Immunodiagnostics segment. While the market anticipates a strong earnings report, much of the positive news is already priced into the stock, suggesting limited upside unless the company provides exceptionally robust forward-looking guidance. The upcoming earnings call will focus on the pace of IGRA adoption an", "sentiment_score": -0.120217, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "What to Expect From Revvity's Next Quarterly Earnings Report", "url": "https://www.inkl.com/news/what-to-expect-from-revvity-s-next-quarterly-earnings-report", "date": "2026-04-12", "summary": "Revvity, Inc. (RVTY) is preparing to announce its fiscal first-quarter earnings for 2026, with analysts anticipating a 1% increase in EPS to $1.02. Despite consistent outperformance in past EPS estimates, RVTY's stock has underperformed the S&P 500 and the Health Care Select Sector SPDR ETF over the last year, partly due to concerns over new global tariffs. Analysts hold a \"Moderate Buy\" consensus rating for RVTY, with an average price target suggesting a 31.6% potential upside.", "sentiment_score": 0.208079, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "What to Expect From Revvity's Next Quarterly Earnings Report", "url": "https://www.barchart.com/story/news/1264071/what-to-expect-from-revvity-s-next-quarterly-earnings-report", "date": "2026-04-12", "summary": "Revvity, Inc. (RVTY) is a health sciences solutions provider valued at $10 billion. The company is expected to announce its fiscal first-quarter earnings for 2026 soon, with analysts projecting a diluted EPS of $1.02, a 1% increase year-over-year. Despite consistent EPS beats, RVTY stock has underperformed the S&P 500 and the Health Care Select Sector SPDR ETF in the past year, partly due to fears surrounding new global tariffs.", "sentiment_score": 0.040098, "sentiment_label": "Neutral", "relevance_score": 0.306454, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "What to Expect From Revvity's Next Quarterly Earnings Report", "url": "https://www.financialcontent.com/article/barchart-2026-4-12-what-to-expect-from-revvitys-next-quarterly-earnings-report", "date": "2026-04-12", "summary": "Revvity, Inc. (RVTY) is expected to announce its fiscal first-quarter earnings for 2026, with analysts anticipating a profit of $1.02 per share. Despite the company consistently surpassing EPS estimates, its stock has underperformed the S&P 500 and the Health Care Select Sector SPDR ETF due to concerns over new global tariffs. Analysts currently have a \"Moderate Buy\" rating on RVTY, with an average price target indicating a significant potential upside.", "sentiment_score": 0.226543, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "(RVTY) Movement as an Input in Quant Signal Sets", "url": "https://news.stocktradersdaily.com/news_release/35/RVTY_Movement_as_an_Input_in_Quant_Signal_Sets_041226095401_1776002041.html", "date": "2026-04-12", "summary": "This article analyzes Revvity Inc. (NASDAQ: RVTY) using AI models to generate trading strategies and signals. It highlights strong near and mid-term sentiment, an exceptional risk-reward setup, and provides specific entry, target, and stop-loss zones for position, momentum breakout, and risk hedging strategies across multiple timeframes.", "sentiment_score": 0.430978, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "ZoomInfo Technologies Receives 'Hold' Rating from Analysts", "url": "https://nationaltoday.com/us/ma/waltham/news/2026/04/12/zoominfo-technologies-receives-hold-rating-from-analysts-1/", "date": "2026-04-12", "summary": "ZoomInfo Technologies (NASDAQ:GTM) has received a consensus 'Hold' rating from analysts, with a mixed outlook on its growth prospects and competitive position. The stock has seen a significant decline from its 52-week high, reflecting uncertainty in the data intelligence market. Investors are keenly awaiting the upcoming Q1 2026 earnings report to gauge the company's future performance.", "sentiment_score": 0.120165, "sentiment_label": "Neutral", "relevance_score": 0.649736, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity’s IGRA Growth Engine Faces Crucial Test—Can It Offset Eroding China and Immunodiagnostics Headwinds?", "url": "https://www.bitget.com/news/detail/12560605360628", "date": "2026-04-11", "summary": "Revvity is facing a critical juncture where the growth from its Interferon-Gamma Release Assay (IGRA) testing segment needs to counteract the declining revenues from the China market and its Immunodiagnostics segment. The market has already priced in strong performance, suggesting that a mere beat on earnings might not drive significant stock rallies. The upcoming earnings call will be crucial for management to provide forward-looking signals and strong full-year guidance to justify the stock's ", "sentiment_score": -0.182723, "sentiment_label": "Somewhat-Bearish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.382, "confidence": 0.38 } }, { "source": "alpha_vantage", "title": "Revvity to Hold Earnings Call on Tuesday, May 5, 2026", "url": "https://www.marketscreener.com/news/revvity-to-hold-earnings-call-on-tuesday-may-5-2026-ce7e50d8d08ff626", "date": "2026-04-10", "summary": "Revvity, Inc. (NYSE: RVTY) announced it will release its first-quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call at 7:30 a.m. ET on the same day to discuss these results, with President and CEO Prahlad Singh and CFO Max Krakowiak leading the call. A live audio webcast will be available on the Investors section of Revvity's website.", "sentiment_score": 0.024256, "sentiment_label": "Neutral", "relevance_score": 0.334672, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity Schedules Q1 2026 Earnings Call", "url": "https://nationaltoday.com/us/ma/waltham/news/2026/04/10/revvity-to-hold-earnings-call-on-tuesday/", "date": "2026-04-10", "summary": "Revvity, Inc., a Waltham-based biotech company, announced it will release its first quarter 2026 financial results before the market opens on Tuesday, May 5, 2026. The company will also host a conference call at 7:30 a.m. ET on the same day to discuss these results. This report is crucial for investors as it provides updates on Revvity's financial performance and product pipeline.", "sentiment_score": 0.135997, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity’s May 5 financial results will confirm the updated outlook—or could prompt a reassessment.", "url": "https://www.bitget.com/amp/news/detail/12560605355781", "date": "2026-04-10", "summary": "Revvity is nearing a critical juncture with its May 5 earnings report, which will determine if the company can sustain its ambitious 2026 financial projections and justify its high share valuation. Investors and analysts are closely watching, as a 'Hold' consensus rating and limited upside potential indicate a market that expects flawless execution. The upcoming results will serve as the first major test of the company's increased full-year guidance since its strong Q4 2025 performance, with any", "sentiment_score": -0.135132, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity to Hold Earnings Call on Tuesday, May 5, 2026", "url": "https://www.businesswire.com/news/home/20260410482955/en/Revvity-to-Hold-Earnings-Call-on-Tuesday-May-5-2026", "date": "2026-04-10", "summary": "Revvity, Inc. (NYSE: RVTY) announced it will release its first quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call at 7:30 a.m. ET on the same day to discuss these results, led by President and CEO Prahlad Singh and CFO Max Krakowiak. A live audio webcast will be available on Revvity's Investors section website.", "sentiment_score": 0.128183, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity to Hold Earnings Call on Tuesday, May 5, 2026", "url": "https://markets.financialcontent.com/stocks/article/bizwire-2026-4-10-revvity-to-hold-earnings-call-on-tuesday-may-5-2026", "date": "2026-04-10", "summary": "Revvity, Inc. announced it will release its first quarter 2026 financial results before market open on Tuesday, May 5, 2026. The company will host a conference call on the same day at 7:30 a.m. ET to discuss these results, with President and CEO Prahlad Singh and CFO Max Krakowiak. A live audio webcast will be available on the Investors section of Revvity's website.", "sentiment_score": 0.073817, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity unveils Signals BioDesign offering", "url": "https://www.tipranks.com/news/the-fly/revvity-unveils-signals-biodesign-offering-thefly-news-2", "date": "2026-04-10", "summary": "Revvity's Signals Software business has launched Signals BioDesign, a new cloud-native molecular cloning solution aimed at streamlining biologics research workflows. The platform is designed for biotech and pharma R&D teams, offering a collaborative digital environment that simplifies complex cloning processes and addresses the limitations of existing tools. This new offering combines essential cloning methodologies with enterprise-grade collaboration features.", "sentiment_score": 0.256838, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity unveils Signals BioDesign offering", "url": "https://www.tipranks.com/news/the-fly/revvity-unveils-signals-biodesign-offering-thefly-news?mod=mw_quote_news", "date": "2026-04-10", "summary": "Revvity's Signals Software business has launched Signals BioDesign, a new cloud-native molecular cloning solution aimed at streamlining biologics research workflows. This platform is designed for biotech and pharma R&D teams to simplify complex cloning processes, enable scalable collaboration, and offer a unified digital environment. It distinguishes itself by combining essential cloning methodologies with enterprise-grade collaboration, addressing limitations found in traditional desktop tools ", "sentiment_score": 0.346488, "sentiment_label": "Somewhat-Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity Launches Signals BioDesign Offering for Biologics Research Workflows", "url": "https://www.marketscreener.com/news/revvity-launches-signals-biodesign-offering-for-biologics-research-workflows-ce7e50d8d980f72d", "date": "2026-04-09", "summary": "Revvity has introduced Signals BioDesign, a new solution aimed at enhancing biologics research workflows. The offering is designed to streamline the discovery and development process of biological therapies. This launch comes amidst recent analyst adjustments to Revvity's price targets, reflecting ongoing market interest in the company's innovations.", "sentiment_score": 0.262672, "sentiment_label": "Somewhat-Bullish", "relevance_score": 0.991607, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity (RVTY) Introduces New Cloud-Based Molecular Cloning Platform", "url": "https://www.gurufocus.com/news/8784664/revvity-rvty-introduces-new-cloudbased-molecular-cloning-platform", "date": "2026-04-09", "summary": "Revvity (RVTY) has launched Signals BioDesign, a new cloud-based platform aimed at enhancing molecular cloning in biologics research for biotech and pharmaceutical companies. While this innovation positions Revvity well, the company faces financial challenges including declining revenue and earnings growth, moderate leverage, and a \"grey area\" Altman Z-Score, indicating investor caution despite a high institutional ownership.", "sentiment_score": 0.080071, "sentiment_label": "Neutral", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Up to 1,000 constructs in one app: Revvity debuts cloud cloning tool", "url": "https://www.stocktitan.net/news/RVTY/revvity-unveils-its-signals-bio-design-offering-to-advance-biologic-surplmrcuzi3.html", "date": "2026-04-09", "summary": "Revvity, Inc. has launched Signals BioDesign, a cloud-native molecular cloning platform aimed at streamlining biologics research workflows for biotech and pharma R&D teams. This solution enables high-throughput construct design for up to 1,000 constructs, integrates with Revvity's Signals One platform, and supports various cloning methodologies. The cloud-native architecture offers enhanced collaboration, centralized data management, and is designed to accelerate therapeutic development and read", "sentiment_score": 0.44208, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity Unveils its Signals BioDesign Offering to Advance Biologic Research Workflows", "url": "https://www.businesswire.com/news/home/20260409192954/en/Revvity-Unveils-its-Signals-BioDesign-Offering-to-Advance-Biologic-Research-Workflows", "date": "2026-04-09", "summary": "Revvity Signals Software is launching Signals BioDesign, a new cloud-native molecular cloning solution designed to streamline biologics research workflows for biotech and pharma R&D teams. This platform simplifies complex cloning processes, enabling scalable, collaborative development in a unified digital environment. It supports various cloning methodologies, high-throughput construct design, and integrates with the Signals One platform, addressing limitations of existing tools and promoting AI", "sentiment_score": 0.428526, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "alpha_vantage", "title": "Revvity Inc. stock outperforms competitors on strong trading day", "url": "https://www.marketwatch.com/data-news/revvity-inc-stock-outperforms-competitors-on-strong-trading-day-669e7888-6dedcba0c3a5?mod=mw_quote_news", "date": "2026-04-08", "summary": "Revvity Inc. (RVTY) shares rose 2.97% to $90.40 on Wednesday, outperforming the broader market. This gain ended a two-day losing streak for the company. The S&P 500 Index and Dow Jones Industrial Average also saw significant increases on the strong trading day.", "sentiment_score": 0.400516, "sentiment_label": "Bullish", "relevance_score": 1.0, "sentiment": { "label": "positive", "score": 0.711, "confidence": 0.71 } }, { "source": "alpha_vantage", "title": "Revvity Sees Growth in Diagnostics, Encounters Challenges in China", "url": "https://www.bitget.com/amp/news/detail/12560605341295", "date": "2026-04-06", "summary": "Revvity (RVTY) is experiencing growth in its diagnostics and high-margin Signals Software segments, positioning it for expansion despite some short-term challenges. The company faces headwinds from reimbursement changes in China, subdued demand from academic and government sectors, and macroeconomic fluctuations, which have led to an underperformance in its stock this year. However, Revvity anticipates an average annual growth rate of 8.7% over the next five years, driven by its strong product l", "sentiment_score": -0.127482, "sentiment_label": "Neutral", "relevance_score": 0.985435, "sentiment": { "label": "positive", "score": 0.44, "confidence": 0.44 } }, { "source": "pubmed", "pmid": "41986715", "title": "mRNA vaccines engage unconventional pathways in CD8(+) T cell priming.", "authors": "Jo S et al.", "journal": "Nature", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41986715/", "sentiment": { "label": "positive", "score": 0.34, "confidence": 0.34 } }, { "source": "pubmed", "pmid": "41974962", "title": "The dual role of TOX in regulating T(H)1 and CD8(+) T cell fate.", "authors": "Kye YC et al.", "journal": "Nature immunology", "date": "2026 Apr 1", "url": "https://pubmed.ncbi.nlm.nih.gov/41974962/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41927314", "title": "Implementing shorter all-oral treatment durations for multidrug-resistant tuberculosis in the UK: from concept to application.", "authors": "Chavda A et al.", "journal": "BMJ open respiratory research", "date": "2026 Apr 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41927314/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41877199", "title": "Machine says go, doctor says no: an ecological momentary assessment analysis examining clinicians' perceptions of, and their antibiotic prescribing behaviour when using rapid molecular diagnostic tests in intensive care.", "authors": "Stewart SF et al.", "journal": "Antimicrobial resistance and infection control", "date": "2026 Mar 2", "url": "https://pubmed.ncbi.nlm.nih.gov/41877199/", "sentiment": { "label": "positive", "score": 0.494, "confidence": 0.49 } }, { "source": "pubmed", "pmid": "41831164", "title": "PDXK Mutation Causes a Late-Onset Pyridoxal 5'-Phosphate-Responsive Peripheral Neuropathy Preceded by Neonatal Seizures: Authors' Reply.", "authors": "Arora A et al.", "journal": "Indian journal of pediatrics", "date": "2026-04-20", "url": "https://pubmed.ncbi.nlm.nih.gov/41831164/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "41270708", "title": "Feasibility of deep learning-based cancer detection in ultrasound microvascular images.", "authors": "Bautista KJB et al.", "journal": "Ultrasonics", "date": "2026-04-20", "url": "https://pubmed.ncbi.nlm.nih.gov/41270708/", "sentiment": { "label": "negative", "score": -0.66, "confidence": 0.66 } }, { "source": "pubmed", "pmid": "41091569", "title": "Cannabis Provenance by Isotope Ratio Analysis.", "authors": "Filer CN", "journal": "Cannabis and cannabinoid research", "date": "2026-04-20", "url": "https://pubmed.ncbi.nlm.nih.gov/41091569/", "sentiment": { "label": "neutral", "score": 0.0, "confidence": 0.0 } }, { "source": "pubmed", "pmid": "40814143", "title": "Neonatal hypoglycaemic brain injury, a common cause of early-childhood epilepsy in India: A prospective longitudinal study on aetiologies and outcomes.", "authors": "Gupta C et al.", "journal": "Developmental medicine and child neurology", "date": "2026-04-20", "url": "https://pubmed.ncbi.nlm.nih.gov/40814143/", "sentiment": { "label": "negative", "score": -0.421, "confidence": 0.42 } } ] } }